Microsoft Surface Tablet: Are Sales Associates Steering Buyers Away from Microsoft’s Surface?

Microsoft’s Surface, which Best Buy just recently started carrying, was not recommended to us by reps without us asking about it specifically. When asked about sales to date, reps noted that the device was new and indicated that early demand has been modest relative to the iPad and Kindle Fire. We would also note that the device was in stock at every store we contacted. We contacted Staples stores in an effort to further gauge Microsoft Surface sales, though our impression from speaking with reps was tablets are not a major seller at Staples. Tellingly, Staples doesn’t currently carry the iPad. When pressed for details, Staples reps indicated that Surface volumes have been modest to date. Most reps told us that the primary appeal to Surface buyers is the ability to run Microsoft Office. Consistent with our Best Buy checks, the Surface was also in stock at all Staples stores we contacted. Outside of the Surface, the Google Nexus 10 was cited as another strong tablet option.

While this news is sure to be disappointing to those at Microsoft Corporation (NASDAQ:MSFT), it is the job of the sales associates at these stores to present buyers with accurate and detailed information. Since the iPad and Kindle are more popular, it only makes sense that the stores would push these tablets first.

What are your thoughts on Microsoft Corporation (NASDAQ:MSFT)’s Surface tablet? Is there any hope of it gaining traction in 2013?

Check back here for more updates on Microsoft Surface Tablet.

Here are three related stories to read if you are interested in learning more:

Verizon Using Microsoft Corporation Surface in Stores – Not For Sale, However

Microsoft Corporation: Is The Surface Tablet a Dud?

Microsoft Corporation’s Surface Tablet Disappointing Thus Far

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!